Phico Therapeutics awarded up to $18.2 million (c.£13.2 million) CARB-X funding to advance SASPject antibacterial therapy through Phase 1 clinical trials.
FDA approves first ADC Therapeutics anti-cancer drug, ZYNLONTA™, for clinical use in patients with relapsed or refractory diffuse large B-Cell Lymphoma.
ET Capital, in collaboration with Carbon13 – the venture builder for the climate emergency, has launched an SEIS fund investing in new businesses focused on making signficant reductions in carbon emissions.
ADC Therapeutics SA, the innovative anti-cancer therapeutics business, has floated on the New York Stock Exchange. Demand for the issue was high with an upsized placing and shares trading at an immediate premium.
ADC Therapuetics announces positive results from pivotal Phase 2 clinical trial of its lead therapeutic.
BBC features the life transforming impact of Oxsight Crystal smart glasses for a patient with Usher’s disease.
ADC Therapeutics Announces First Patients Dosed in Phase I/II Clinical Trial of ADCT-602 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
Phico Therapeutics awarded Innovate UK funding for £1.4 million ($1.87M) antibacterial therapy project.